Kevin Kunzmann

The SGLT2 inhibitor from Janssen has shown significant benefit for reducing progression to end-stage kidney disease, as well as risk for major adverse cardiovascular events.

How can physicians and specialists navigate testing options and potential risk factors to ensure patients are diagnosed and treated expediently and accurately?

A new study from ERS showed the technological material common among training athletes could help physicians monitor patients with COPD.

There has been significant changes in understanding surrounding food allergy testing. What do parents need to know?

A new study from CCR West compared the JAK inhibitor therapy to competitors across a clinical trial program involving 5 pivotal phase 3 studies.

The indication for the add-on monoclonal antibody makes it the first approved therapy for children with the rare vasculitis conditions.

A new study from the ERS International Congress shows a trio of air pollutants are associated with significant increases in all-cause infant mortality in the UK.

The approval is based on findings showing patients on the drug plus VTd had a 53% reduction in risk of disease progression or death, compared to lone VTd.

The Proclaim XR recharge-free system provides relieve through a low-dose proprietary BurstDR stimulation waveform, which mimics natural brainwave patterns that change pain signals traveling from the spinal cord to the brain.

A comparative assessment of step-up therapy strategies for black patients with inadequately controlled asthma showed varying responses.

A cohort assessment of patients treated in a rural academic-based clinic finds just 10% of patients were vaccinated for the disease their RA therapies put them at more risk for.

A new study shows adherence to current ACR guidelines for therapy results in improved disease activity scores.

The high-sensitivity test may prove to be significantly beneficial for at-risk females, who generally have lower troponin levels than men.

The vaccine is approved for use in high-risk individuals, and will be includied in the US Strategic National Stockpile.

New findings show, despite women making up a greater rate of internal medicine residents, subspecialty fellowships are at a greater disparity now than in 1991.

After receiving FDA approval for add-on adult severe chronic rhinosinusitis with nasal polyps treatment this June, the biologic has reported significant improvement in 24- and 52-week outcomes.

Outside of CPAP, what therapies—invasive and non-invasive—exist for patients?

A new study shows that approximately one-quarter of adults aged 18-34 years old with a medical condition have used marijuna in the past month.

The therapy becomes the first oral GLP-1 agonist approved for the treatment of A1C reduction.

The approved test detects Babesia parasites in red blood cells—an advancement due to the inability to detect parasite in traditional plasma or serum samples.

The human monoclonal antibody was previously approved for the treatment of adults with plaque psoriasis in July 2017.

How recent trends in heart failure research have shown more priority to patient quality of life outcomes.

A clinical discussion on the underlooked, undertreated, and underperforming facets of a public health crisis.

How does the broadened sacubitril/valsartan assessment influence the treating confidence of a clinician?

New findings from the trial show daily adherence to the fluid monitoring ReDS system dropped HF patient readmission risk by 58%.

What was learned from the newest data for sacubitril/valsartan for HFrEF?

How new dapagliflozin findings from ESC 2019 and HFSA 2019 shape our understanding of the SGLT-2 inhibitor's benefit.

Emerging mechanical therapy options have given life to a field which has gone under severe recharacterization in an era of increased obesity.

Hospital costs, length of stay, and even mortality were shown to be significantly cut in TAVR patients with comorbid heart failrue than those without, new data shows.

The headline drug class has been quickly added to cardiologists' toolsets, amid more and more phase 3 data.